A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
OBJECTIVES: This report reviews the clinical effectiveness and cost-effectiveness of adalimumab, etanercept and infliximab, agents that inhibit tumour necrosis factor-alpha (TNF-alpha), when used in the treatment of rheumatoid arthritis (RA) in adults. DATA SOURCES: Electronic databases were search...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2006
|
| _version_ | 1826267539917766656 |
|---|---|
| author | Chen, Y Jobanputra, P Barton, P Jowett, S Bryan, S Clark, W Fry-Smith, A Burls, A |
| author_facet | Chen, Y Jobanputra, P Barton, P Jowett, S Bryan, S Clark, W Fry-Smith, A Burls, A |
| author_sort | Chen, Y |
| collection | OXFORD |
| description | OBJECTIVES: This report reviews the clinical effectiveness and cost-effectiveness of adalimumab, etanercept and infliximab, agents that inhibit tumour necrosis factor-alpha (TNF-alpha), when used in the treatment of rheumatoid arthritis (RA) in adults. DATA SOURCES: Electronic databases were searched up to February 2005. REVIEW METHODS: Systematic reviews of the literature on effectiveness and cost-effectiveness were undertaken and industry submissions to the National Institute for Health and Clinical Excellence (NICE) were reviewed. Meta-analyses of effectiveness data were also undertaken for each agent. The Birmingham Rheumatoid Arthritis Model (BRAM), a simulation model, was further developed and used to produce an incremental cost-effectiveness analysis. RESULTS: Twenty-nine randomised controlled trials (RCTs), most of high quality, were included. The only head-to-head comparisons were against methotrexate. For patients with short disease duration ( |
| first_indexed | 2024-03-06T20:55:45Z |
| format | Journal article |
| id | oxford-uuid:3931d077-dbac-4fe0-a24b-a6d6e5afb6df |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:55:45Z |
| publishDate | 2006 |
| record_format | dspace |
| spelling | oxford-uuid:3931d077-dbac-4fe0-a24b-a6d6e5afb6df2022-03-26T13:54:09ZA systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:3931d077-dbac-4fe0-a24b-a6d6e5afb6dfEnglishSymplectic Elements at Oxford2006Chen, YJobanputra, PBarton, PJowett, SBryan, SClark, WFry-Smith, ABurls, A OBJECTIVES: This report reviews the clinical effectiveness and cost-effectiveness of adalimumab, etanercept and infliximab, agents that inhibit tumour necrosis factor-alpha (TNF-alpha), when used in the treatment of rheumatoid arthritis (RA) in adults. DATA SOURCES: Electronic databases were searched up to February 2005. REVIEW METHODS: Systematic reviews of the literature on effectiveness and cost-effectiveness were undertaken and industry submissions to the National Institute for Health and Clinical Excellence (NICE) were reviewed. Meta-analyses of effectiveness data were also undertaken for each agent. The Birmingham Rheumatoid Arthritis Model (BRAM), a simulation model, was further developed and used to produce an incremental cost-effectiveness analysis. RESULTS: Twenty-nine randomised controlled trials (RCTs), most of high quality, were included. The only head-to-head comparisons were against methotrexate. For patients with short disease duration ( |
| spellingShingle | Chen, Y Jobanputra, P Barton, P Jowett, S Bryan, S Clark, W Fry-Smith, A Burls, A A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. |
| title | A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. |
| title_full | A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. |
| title_fullStr | A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. |
| title_full_unstemmed | A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. |
| title_short | A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. |
| title_sort | systematic review of the effectiveness of adalimumab etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost effectiveness |
| work_keys_str_mv | AT cheny asystematicreviewoftheeffectivenessofadalimumabetanerceptandinfliximabforthetreatmentofrheumatoidarthritisinadultsandaneconomicevaluationoftheircosteffectiveness AT jobanputrap asystematicreviewoftheeffectivenessofadalimumabetanerceptandinfliximabforthetreatmentofrheumatoidarthritisinadultsandaneconomicevaluationoftheircosteffectiveness AT bartonp asystematicreviewoftheeffectivenessofadalimumabetanerceptandinfliximabforthetreatmentofrheumatoidarthritisinadultsandaneconomicevaluationoftheircosteffectiveness AT jowetts asystematicreviewoftheeffectivenessofadalimumabetanerceptandinfliximabforthetreatmentofrheumatoidarthritisinadultsandaneconomicevaluationoftheircosteffectiveness AT bryans asystematicreviewoftheeffectivenessofadalimumabetanerceptandinfliximabforthetreatmentofrheumatoidarthritisinadultsandaneconomicevaluationoftheircosteffectiveness AT clarkw asystematicreviewoftheeffectivenessofadalimumabetanerceptandinfliximabforthetreatmentofrheumatoidarthritisinadultsandaneconomicevaluationoftheircosteffectiveness AT frysmitha asystematicreviewoftheeffectivenessofadalimumabetanerceptandinfliximabforthetreatmentofrheumatoidarthritisinadultsandaneconomicevaluationoftheircosteffectiveness AT burlsa asystematicreviewoftheeffectivenessofadalimumabetanerceptandinfliximabforthetreatmentofrheumatoidarthritisinadultsandaneconomicevaluationoftheircosteffectiveness AT cheny systematicreviewoftheeffectivenessofadalimumabetanerceptandinfliximabforthetreatmentofrheumatoidarthritisinadultsandaneconomicevaluationoftheircosteffectiveness AT jobanputrap systematicreviewoftheeffectivenessofadalimumabetanerceptandinfliximabforthetreatmentofrheumatoidarthritisinadultsandaneconomicevaluationoftheircosteffectiveness AT bartonp systematicreviewoftheeffectivenessofadalimumabetanerceptandinfliximabforthetreatmentofrheumatoidarthritisinadultsandaneconomicevaluationoftheircosteffectiveness AT jowetts systematicreviewoftheeffectivenessofadalimumabetanerceptandinfliximabforthetreatmentofrheumatoidarthritisinadultsandaneconomicevaluationoftheircosteffectiveness AT bryans systematicreviewoftheeffectivenessofadalimumabetanerceptandinfliximabforthetreatmentofrheumatoidarthritisinadultsandaneconomicevaluationoftheircosteffectiveness AT clarkw systematicreviewoftheeffectivenessofadalimumabetanerceptandinfliximabforthetreatmentofrheumatoidarthritisinadultsandaneconomicevaluationoftheircosteffectiveness AT frysmitha systematicreviewoftheeffectivenessofadalimumabetanerceptandinfliximabforthetreatmentofrheumatoidarthritisinadultsandaneconomicevaluationoftheircosteffectiveness AT burlsa systematicreviewoftheeffectivenessofadalimumabetanerceptandinfliximabforthetreatmentofrheumatoidarthritisinadultsandaneconomicevaluationoftheircosteffectiveness |